Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva/Ivax Deal

This article was originally published in The Tan Sheet

Executive Summary

Teva Pharmaceuticals' acquisition of fellow generics firm Ivax is expected to close on Jan. 12, 2006, the firms state in a joint release Dec. 23. The Israeli firm Teva and the Miami, Fla.-based Ivax have now signed a consent order for submission to FTC, which is "the last remaining regulatory condition to the consummation of the transaction," the release states. The deal cannot close until FTC approves a consent order, they note. The planned acquisition was announced in July 2005 ("The Tan Sheet" Aug. 1, 2005, p. 11)...

You may also be interested in...

Teva Broadens Private Label OTC Offerings With Ivax Acquisition

Teva's planned acquisition of Ivax adds a wide range of private label OTCs to the firm's generic drug portfolio

Finance Watch: Biopharma VC Deals Hit New Record Of $27.4bn In 2020

Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.

Teva Takes On Amneal With Second US NuvaRing Rival

Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts